T1	p 14 33	vasodilator therapy
T2	p 51 80	in congestive heart failure .
T3	p 239 342	patients with moderate to severe congestive heart failure . Seventeen patients on chronic digitalis and
T4	p 1001 1009	systolic
T5	p 1057 1064	therapy
T6	p 1169 1225	patients with moderate to severe chronic heart failure .
T7	i 6 33	Chronic vasodilator therapy
T8	i 39 50	flosequinan
T9	i 143 154	flosequinan
T10	i 159 162	new
T11	i 183 212	arterial and venous dilator ,
T12	i 394 407	flosequinan (
T13	i 416 428	or placebo (
T14	i 853 864	flosequinan
T15	i 885 893	effected
T16	i 1037 1064	chronic vasodilator therapy
T17	i 1070 1112	flosequinan to standard digitalis-diuretic
T18	o 476 513	symptomatology , exercise performance
T19	o 516 545	and left ventricular function
T20	o 668 712	symptom scores and functional classification
T21	o 764 782	Flosequinan evoked
T22	o 809 834	maximal exercise capacity
T23	o 896 907	progressive
T24	o 920 940	resting heart rate ,
T25	o 973 1020	indices of left ventricular systolic function .
T26	o 1368 1405	clinical improvement , subpopulations